spruceBIOSCIENCES

EXPLORE THE POSSIBILITY OF CHANGING YOUR CLASSIC CAH JOURNEY

CAHmelia 203 · 204

There have been no new treatment options for classic Congenital Adrenal Hyperplasia (CAH) since the 1950's.

About the Clinical Trial

A randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of tildacerfont in adults with classic congenital adrenal hyperplasia, followed by an open-label treatment with tildacerfont. The sponsor of this clinical trial is Spruce Biosciences.

Trial Purpose

The primary purpose of the CAHmelia program is to assess if tildacerfont is effective in lowering androgens (testosterone-related hormones) and daily glucocorticoid doses in adults with classic CAH. The CAHmelia studies are dedicated to exploring solutions for people living with classic CAH.

About Tildacerfont

Tildacerfont is a type of oral, once-daily investigational drug that is NOT a steroid. By reducing the amount of androgens (testosterone-related hormones) your body makes, tildacerfont may improve your classic CAH symptoms. This investigational drug will not replace your steroid treatment but may allow you to manage your condition with lower steroid doses.

Population

Adults at least 18 years of age with classic CAH (including salt-wasting and simple virilizing) taking steroids daily (glucocorticoids with or without mineralocorticoids).

To learn more about the CAHmelia program:

- visit us at www.CAHstudy.com
- email CAHmelia@sprucebiosciences.com

SCAN ME

Scan to learn more

A survey of 113 CAH participants stated that they do not feel sufficiently informed about their treatment:

51% of participants felt they did not have enough access to information to make an informed choice about GC treatment

66% of participants are willing to change their current regimen if they could lower their dose of steroid

Data on file Spruce Biosciences participant survey 2022